Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28448111 | 0.75 | IDO1 (0.39) | IDO1TDO2CYP2C9ALDH1A1CYP3A4 | |
| SCHEMBL7492439 | 0.75 | ESR1 (0.54) | CYP2C19CYP2C9ALDH1A1CYP3A4HTT | |
| SCHEMBL9252331 | 0.75 | IDO1 (0.40) | IDO1TDO2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL8634592 | 0.75 | ALOX15 (0.36) | ALDH1A1CYP3A4ALOX15ESR1 | |
| SCHEMBL60173 | 0.75 | ALDH1A1 (0.40) | ALDH1A1ESR1 | |
| SCHEMBL28899530 | 0.75 | ESR1 (0.34) | ESR1 | |
| SCHEMBL6120023 | 0.75 | APLNR (0.32) | IDO1TDO2CYP2C19ALDH1A1CYP3A4 | |
| SCHEMBL7776205 | 0.73 | CA1 (0.46) | IDO1TDO2CYP2C19ALDH1A1CYP3A4 | |
| SCHEMBL755423 | 0.73 | — | — | |
| SCHEMBL2068749 | 0.72 | IDO1 (0.36) | IDO1TDO2CYP2C19CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| CN-101048414-B | Fused tricyclic derivatives for the treatment of psychotic disorders | GLAXO GROUP LTD | 2011-09-07 | — | — | CN | disclosed |
| CN-101048414-A | Fused tricyclic derivatives for the treatment of psychotic disorders | GLAXO GROUP LTD (GB) | 2007-10-03 | — | — | CN | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
| EP-1127917-B1 | Flame-retardant thermoplastic resin composition | AJINOMOTO KK (JP) | 2005-11-30 | — | — | EP | disclosed |
| US-6500889-B2 | BROMINATED FLAME RETARDANT, DOLOMITE AND ONE OF: HYDROTALCITE, ZINC-SUBSTITUTED HYDROTALCITE, OR ZEOLITE; HEAT STABILIZING | AJINOMOTO CO., INC. (JP) | 2002-12-31 | — | — | US | disclosed |
| US-20010044488-A1 | Flame-retarded thermoplastic resin composition | AJINOMOTO CO. INC. (JP) | 2001-11-22 | — | — | US | disclosed |
| EP-1127917-A1 | Flame-retardant thermoplastic resin composition | Ajinomoto Co., Inc. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | IDO1 1800/4885TDO2 2905/4885CYP2C19 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.